(R)-Lisofylline (Synonyms: (−)-Lisofylline,(R)-LSF) |
| رقم الكتالوجGC12578 |
(R) -Lisofylline ((R) -Lisophylline) هو (R) -enantiomer لمستقلب البنتوكسيفيلين مع خصائص مضادة للالتهابات
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 100324-81-0
Sample solution is provided at 25 µL, 10mM.
Lisofylline (LSF) is a potent anti-inflammatory agent. LSF is a chiral metabolite of pentoxifylline. (R)-LSF is the biologically active isomer of LSF [1].
In vitro: Lisofylline preserved β-cell insulin secretion and inhibited DNA damage of islets in the presence of IL-1β [2]. Simultaneous application of LSF and cytokines to INS-1 cells restored insulin secretion, mitochondrial membrane potential, MTT metabolism, and cell viability to control levels. LSF increased β-cell MTT metabolism as well as insulin release and glucose responsiveness [3].
In vivo: In rats subjected to hemorrhagic shock and resuscitation, LSF increased the intestinal and hepatic blood flow. Treatment with LSF (15 mg/kg) ameliorated the development of mucosal damage and hyperpermeability. Rats treated with LSF showed lower plasma concentrations of the intracellular hepatic enzyme, aspartate aminotransferase. LSF treatment increased concentrations of adenosine triphosphate in intestinal and hepatic tissue [1]. In NOD mice, lisofylline suppressed IFN-γ production, reduced the onset of insulitis and diabetes, and inhibited diabetes after transfer of splenocytes from Lisofylline-treated donors to NOD.scid recipients [2].
References:
[1] Wattanasirichaigoon S, Menconi M J, Fink M P. Lisofylline ameliorates intestinal and hepatic injury induced by hemorrhage and resuscitation in rats[J]. Critical care medicine, 2000, 28(5): 1540-1549.
[2] Yang Z D, Chen M, Wu R, et al. The anti-inflammatory compound lisofylline prevents Type I diabetes in non-obese diabetic mice[J]. Diabetologia, 2002, 45(9): 1307-1314.
[3] Chen M, Yang Z, Wu R, et al. Lisofylline, a novel antiinflammatory agent, protects pancreatic β-cells from proinflammatory cytokine damage by promoting mitochondrial metabolism[J]. Endocrinology, 2002, 143(6): 2341-2348.
| Cas No. | 100324-81-0 | SDF | |
| المرادفات | (−)-Lisofylline,(R)-LSF | ||
| Chemical Name | 3,7-dihydro-1-[(5R)-5-hydroxyhexyl]-3,7-dimethyl-1H-purine-2,6-dione | ||
| Canonical SMILES | O=C(N(C)C1=C2N(C)C=N1)N(CCCC[C@H](O)C)C2=O | ||
| Formula | C13H20N4O3 | M.Wt | 280.3 |
| الذوبان | ≤25mg/ml in ethanol;20mg/ml in DMSO;15mg/ml in dimethyl formamide | Storage | Store at -20°C, stored under nitrogen |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.5676 mL | 17.838 mL | 35.6761 mL |
| 5 mM | 0.7135 mL | 3.5676 mL | 7.1352 mL |
| 10 mM | 0.3568 mL | 1.7838 mL | 3.5676 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 28 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *